e-learning
resources
Vienna 2012
Monday, 03.09.2012
Asthma: mechanisms of airway inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice
M. Wegmann, L. Lunding, Z. Orinska, D.M. Wong, R.A. Manz, H. Fehrenbach (Borstel, Germany)
Source:
Annual Congress 2012 - Asthma: mechanisms of airway inflammation
Session:
Asthma: mechanisms of airway inflammation
Session type:
Thematic Poster Session
Number:
2370
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Wegmann, L. Lunding, Z. Orinska, D.M. Wong, R.A. Manz, H. Fehrenbach (Borstel, Germany). Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice. Eur Respir J 2012; 40: Suppl. 56, 2370
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses.
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Relationship between pre-treatment specific IgE and the response to omalizumab therapy
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Monitoring free serum IgE in severe asthma patients treated with omalizumab
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Source: Eur Respir J 2001; 18: 254-261
Year: 2001
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 47s
Year: 2005
Returning asthma symptoms correlate with free IgE upon omalizumab cessation
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Free serum IgE suppression with omalizumab and clinical outcomes in asthma
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Early treatment response may predict long-term mepolizumab benefit in severe asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Anti-IgE treatment in children with severe intrinsic asthma
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept